OR WAIT 15 SECS
Omnicare Clinical Research announces the re-branding of the company under the name Theorem Clinical Research. The brand launch marks the final step in the CRO's separation from its former parent company in a deal that was finalized this spring.
Nautic Partners, LLC, a private equity firm based in Providence, R.I., acquired the CRO in a transaction publicized in April. The signing of the deal not only made official the separation of Omnicare Clinical Research from former parent company, Omnicare, Inc., it accomplished the company‟s most visible step in achieving the long-identified goal: to stand on its own and deliver results the way that clients need.
Now, under the new name, Theorem Clinical Research will bring its more than two decades of experience and industry leadership to manage complex trials. With approximately 1,000 dedicated professionals and locations around the globe, Theorem Clinical Research will continue to provide full-service clinical trial management, with a continued focus on its core CRO (Early Phase, Phase II/III, Late Phase) and its specialized business units:
· Medical Device
· Technical Services (Biometrics & Clinical Data Management)
“The re-branding of the company is not something that happened overnight,” says Dr. James Pusey, President & CEO, Theorem Clinical Research. “This is 25 years in the making. We are now able to be more agile and efficient since we are now in the driver‟s seat of our own company. We strive to be able to work the way our clients do; from our specialized business units to our 32 locations, Theorem Clinical Research (aims) to give clients exactly what they need.”
Theorem will be at the 47th Annual Drug Information Association (DIA) Meeting, June 19-23 in Chicago to kick-off the new brand. Visit them at Booth 529.